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Renal cell carcinoma is rarely diagnosed during pregnancy. Its management is a real challenge
due to the sparse literature and lack of standard guidelines. In this situation, the diagnosis is
often delayed as the clinical presentation might resemble other pregnancy-related disorders
but it should be one of the diagnostic possibilities in women with recurrent or refractory urinary
tract symptoms, renal pain, or mass that could be palpated. Diagnostic approach may include
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Oncologyultrasound examination and sometimes magnetic resonance imaging. If localized, surgery would
be the preferred line of treatment. Other treatment modalities, end results of treatment, and
review of literature of this rare association will be presented.
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Cancer diagnosis during pregnancy is a rare event. An oncol-
ogist can encounter this case in one of two clinical scenarios;
either cancer is diagnosed for the first time in a pregnant
female or incidental pregnancy occurs during cancer treat-
ment.Treatment of cancer during pregnancy represents a med-
ical dilemma. As pregnant women are usually excluded fromclinical trials and due to the rarity of the event, no solid data
can support the treatment decision in such setting [1]. Also,
the impact of abortion or keeping pregnancy till labor, on
prognosis of cancer together with the safety and efficacy of
cancer treatment on the maternal and fetal health is not known
in many occasions [2].
The landscape of renal cell carcinoma management has
changed during the past few years, but surgery remains the
main stay modality, and currently there is no role for adjuvant
therapy. New targeted agents with proven efficacy in
advanced, or metastatic renal cell carcinoma have been devel-
oped. However, the effect of these new agents on fetal and
maternal outcomes is poorly studied [3].
The aim of this article was to revise the medical literature
for data pertinent to this group of patients, aiming to provide
answers to questions regarding management of these patients.
Epidemiology and risk factors
Renal cell carcinoma represents about 3% of solid tumors in
adults with a slight male predominance [4]. An increase in inci-
dence has been observed during the last two decades, with
reports of downward shift of tumor stage and size in many
clinical series [4]. Obesity, smoking and hypertension are estab-
lished risk factors for renal cell carcinoma [5]. High parity
among women and other reproductive and hormonal factors
has been studied as potential risk factors, but no direct causal
effect is evident up till now [4,5]. Since 1980s, steroid receptors
were found on normal and cancerous renal cell tissue. Estrogen
can induce renal cell carcinoma in laboratory mice. Adipose
tissue in obese women is a source of estrogen that may play
a role in increasing the risk for RCC [6]. Treatment with
progesterone was explored in the past for treatment of meta-
static RCC, but abandoned due to unproved efficacy [7].
Accordingly; it was assumed that a possible correlation
between hormonal factors and RCC development exists,
although the underlying mechanism is not fully understood.
During pregnancy, estrogen and progesterone reach to a
high peak. High parity (P5 pregnancies lasting for more than
4 months) was associated with almost doubling of risk for
RCC in comparison with nulliparous women in many reports
[8–10]. However, other studies did not show the same associa-
tion [11,12]. Only one trial showed a strong association for
clear cell adenocarcinoma subtype, although the same trial
did not show association with live births [13].
A meta-analysis including 14 studies (5 cohort studies, one
nested case control, and 8 case control studies) that were pub-
lished in 2013 concluded that ever parity, i.e. with a history of
at least one pregnancy and increased parity numbers are asso-
ciated with an increased risk of kidney cancer [14].
Oral contraceptives were associated with risk reduction in
some series [12], and age of menarche, hysterectomy and age
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[8–12]. Hypertension is a well-established risk factor for
RCC [4,5]. About 18% of cases diagnosed with RCC during
pregnancy presented with hypertension [15]. The risk of
RCC is dependent on the duration of hypertension; secondary
hypertension during pregnancy is of short duration as it
develops during the second trimester [4,5]. It is so unlikely to
consider gestational hypertension a risk factor for RCC. In
some cases, RCC may induce hypertension with improvement
in blood pressure levels after nephrectomy. In a case report of
a patient with hypertension during the first trimester of preg-
nancy, hypertension was reported to be a result of extrinsic
compression of renal artery by the tumor. This conclusion
was supported by the resolution of hypertension after nephrec-
tomy [16].
VHL and Xp11.2 translocations are among the most com-
monly noted chromosomal apparitions in renal cell carcinoma.
Only two cases harboring Xp11.2 translocations were reported
with one of them presented with placental metastases [17,18].
However, the number of cases is too small to generate a
hypothesis regarding the association between these genetic
factors and RCC during pregnancy.
Diagnosis and radiology
The choice of radiological modality in a pregnant woman has
to take two factors into consideration; the acuity of staging
with the least radiation exposure to the fetus.
Proper radiological staging requires CT scan for chest,
abdomen and pelvis. MRI can replace CT when in staging of
the primary tumor and in detection of renal vein involvement.
The role of PET-CT is not well established for staging of RCC.
Isotopic bone scan and CT brain are symptom guided investi-
gations and are not required as a part of the initial staging [19].
Finally after diagnosis, renal scintigraphy may be needed to
assess kidney function reserve before nephrectomy [19]. The
safest diagnostic imaging test during pregnancy is ultrasound,
with no teratogenicity or carcinogenesis. There is an increase in
cases diagnosed as incidental finding during routine ultrasound
examination for antepartum care. Ultrasound has a sensitivity
to detect lesions more than 3 cm comparable to that of CT
[15]. Plain X ray can be performed with minimal radiation
exposure to the fetus if the abdomen was properly shielded.
A CT scan that does not include the gravid uterus in the
field-of-view results in negligible fetal dose and may be
performed in pregnancy without risk to the fetus. A standard
single CT scan through the gravid uterus results in a fetal dose
of 25 mGy or less [20]. However, the possible teratogenic effect
in this non-emergency setting is not preferred. The sensitivity
of MRI in detecting pulmonary lesions is inferior to CT.
Gadolinium contrast medium is better avoided, as it can cross
the placenta and may induce fetal hypothyroidism [21].
PET-CT with an 18F-2-fluoro-2-deoxy-D-glucose injection
(FDG) is also contraindicated during pregnancy because of the
fetal radiation exposure associated with the CT component of
the study. Generally, PET-CT is not a well-established staging
method with any significant benefit that may outweigh the
risks [22].
Whole body MRI is an emerging method for staging of
solid tumors; it has sensitivity comparable to skeletal Scintig-
raphy for assessment of skeletal deposits [21]. However, itssensitivity in detecting pulmonary lesions in comparison with
CT chest remains unknown. Lastly, Doppler studies can be
used to substitute renal scintigraphy for patient planned to
be submitted to nephrectomy for assessment of function of
the other kidney.
Biopsy is not mandatory for diagnosis, as radiological stud-
ies usually provide sufficient findings for diagnosis prior to
surgery. Core biopsy is recommended in selected cases, mainly
in patients with small tumors who are candidates for active
surveillance, local ablative therapies (i.e. radiofrequency abla-
tion and cryosurgery), patients with solitary kidney and
patients with metastatic disease before initiating targeted ther-
apies [23].
The differential diagnosis of renal masses includes inflam-
matory, benign and malignant lesions other than renal cell
carcinoma. Cystic lesions are usually benign.
Clinical picture and tumor characteristics
A series of review articles were published studying the clinical
presentation and management of renal cell carcinoma with
pregnancy [15,21,22]. The last report included articles pub-
lished till April 2013, with a total of 102 cases reported. We
searched the literature published till February 2015, and addi-
tional four cases were found, a case of renal cell carcinoma
during pregnancy presented with IVC tumor thrombus [23],
a case of rapidly enlarging chromophobe renal cell carcinoma
[24], a case of renal cell carcinoma diagnosed during the 14th
week of gestation [25] and a case of metastatic renal cell carci-
noma that became pregnant and experienced massive disease
progression during pregnancy [26] (Table 1).
Incidental finding during routine antepartum examination
was reported in many cases [17,24,27]. The incidence of acci-
dently discovered cases is expected to increase due to increased
utilization of ultrasonography for antepartum care. On the
other hand, the clinical presentation with abdominal pain,
distension, urinary tract infection and hypertension could be
obscured by pregnancy and cause delay in diagnosis. The main
reported presenting symptoms are as follows: pain (50% of
cases), hematuria (47%), hypertension (18%) and the classical
triad of hematuria, pain and palpable mass (26%). Other less
frequent presentations (hemolytic anemia, hypercalcemia, rup-
ture of tumoral cyst) were also reported.
Five cases were reported with metastatic disease during
pregnancy [18,28], and the remaining were diagnosed with less
advanced disease, usually during the second and third trime-
sters of pregnancy, and few cases were reported during the first
trimester [24,27].
Histopathological subtypes included 89 cases with clear cell
carcinoma, 3 cases with chromophobe RCC, nephroblastomas
in 8 cases, angiosarcomas in 2, and carcinoid, capsular
osteoadenocarcinoma, renal pelvis carcinoma and lymphoma
in one patient each [15].
Management
Standardized guidelines for management are unavailable due
to the rarity of this diagnosis and the decision is individualized
for each case, putting in consideration the welfare of mother
and fetus. A multidisciplinary team including oncologist
(surgical and medical), gynecologist, radiologist and urologist
Table 1 Clinical and histopathological features of cases diagnosed with RCC during pregnancy.
No. %
Maternal age at diagnosis (21–52)y
Pathology
Adenocarcinoma 89 84
Chromophobic 3 2.8
Nephroblastoma 8 7.7
Othersa 6 5.7
Stage at diagnosis
Localized 103 98.7
Metastatic 2b 1.3
Gestational age at diagnosis
First trimester 6 5.7
Second trimester 11 9.6
Third trimester 3 2.7
Not reported 85 82
Timing of surgery
Before labor 13 12.5
Spontaneously with labor 2 2.7%
After labor 4
Termination of pregnancy 2
a Other histopathological types include the following: two cases with Angiosarcoma, one case with Carcinoid, one with capsular osteoade-
nocarcinoma, one with Renal pelvis carcinoma and one with lymphoma.
b One case diagnosed with renal cell carcinoma 4 years before gestation, presented during pregnancy with rapid increase in size of previously
existed metastases.
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sion with the mother and the explanation of expected risks for
each treatment modality is a must, with respect to her wishes
and concerns regarding the fetal safety.
It is unknownwhether abortionmay improve the outcome of
treatment or not, and the scarce number of reported cases is not
allowing for a comparative study with their matched stage to
draw a conclusion on the impact of pregnancy on tumor behav-
ior. However, in most of the reported cases the patients had a
smooth treatment course with good maternal outcomes. Most
of them gave birth to healthy viable children. In a review article
published in Nature 2010, termination of pregnancy was
advised once diagnosis is established. This recommendation is
contradicting the conclusion drawn by many authors, together
with the outcomes of treatment reported in the literature where
smooth recovery with treatment outcomes comparable to those
non pregnant patients. However, termination of pregnancy
could be considered in patients with metastatic disease [29].
Surgery
Nephrectomy (radical or nephron sparing surgery) remains a
pivotal part of management of RCC, even in metastatic
disease, where radical nephrectomy is done before systemic
treatment. Nephron sparing surgery could be carried out in
patients with small tumors.
During pregnancy, the timing and the approach of surgery
are two important issues. Fetal maturity and the relatively
slow doubling time of RCC (300–500 days) are the main fac-
tors guiding the timing for surgery. Patient diagnosed during
the first and the third trimester could go for surgical resection
immediately after diagnosis, and for patients diagnosed during
the second trimester the decision is not straightforward.During second trimester, surgical manipulations may induce
uterine contractions causing spontaneous abortion; also
hypotension during surgery caused by blood loss can lead to
fetal hypoxia with detrimental effect on the fetus [30]. The
surgery could be delayed till fetal lung became mature by the
28th week of gestation or even postpartum in some reports
[27,30]. Only two cases had spontaneous cesarean section
and surgical resection of the tumor, as the cesarean section
and nephrectomy were performed through different incisions
and different positions [31–33].
However, second trimester is considered by some authors as
the safest time for surgical intervention. Surgical intervention
becomes difficult as the uterus enlarges, and many authors
prefer to delay surgery when the patient presented with RCC
during the late second trimester, while surgery could be consid-
ered safe during early second trimester [34].
The surgical approach either laparoscopic or open surgery,
trans peritoneal or retroperitoneal is governed by the tumor
site, size and the expertise of the surgical team.
Systemic treatment
The landscape of treatment for metastatic renal cell carcinoma
has changed over the past decade. Chemotherapy and hor-
monal treatment (progesterone) have been abandoned and
replaced with targeted therapy. Choice of treatment depends
on the pathology (clear versus non-clear), and the presence
of short survival predictors. The current treatment options
are multikinase inhibitors (sunitinib, sorafenib, axitinib and
pazopanib), mTOR inhibitors (everolimus and temsirolimus),
anti-angiogenic agents (bevacizumab) and immunological
agents (high dose interleukin 2 and recently check-point inhibi-
tors). The safety of these drugs during pregnancy is poorly
RCC and pregnancy 579studied; data are available only from animal studies. The US
FDA categorizes drugs according to their safety during preg-
nancy into five main categories. Drugs classified as category
D shall be avoided during pregnancy as there is positive
evidence of human fetal risk [35].
Sunitinib [36], sorafenib [37], axitinib [38], pazopanib [39]
and temsirolimus [40] are classified as group D, while beva-
cizumab [41] and everolimus [42] are categorized C and D.
Indeed; these drugs are used for other indications besides
RCC. For example, everolimus is used as immunosuppressant
for patients undergoing allogenic organ (hepatic and renal)
transplantation. Bevacizumab is used for intravenous injection
while interferon is used for the treatment of HCV. These
agents are categorized as group C for these indications but
not for oncological indications.
This double categorization could be confusing; the safety of
bevacizumab was not studied for RCC during pregnancy [43].
The literature studied the safety of intravenous usage only. The
same for everolimus, as there is case report reported its safety
during pregnancy in renal transplant patient. No literature is
currently available for their usage for RCC in pregnant
women.
Chemotherapy is usually avoided during the first trimester
of pregnancy but can be safely administered during the second
and the third trimesters. On the contrary, monoclonal antibod-
ies can be used during the first trimester and must be avoided
during the second and the third trimesters. This is explained by
the transportation mechanism for monoclonal antibodies that
is not established during the first trimester, but is established
later on [44]. Proleukin [45] (Interleukin) is categorized as
category C, with no evidence of teratogenicity. However, the
significant toxicity noted with the use of IL-2 must be
considered.
Conclusions
Renal cell carcinoma during pregnancy is a rare clinical situa-
tion. Its diagnosis is often delayed and its management is a real
challenge. Termination of pregnancy is not advised except in
patients with rapidly growing tumors; otherwise surgery could
be postponed till after or during delivery. In case of a localized
disease, surgery is the standard line of treatment. For systemic
disease, the role of chemotherapy, IL-2, and hormonal treat-
ment has been abandoned and replaced with targeted therapy.
However, TKIs, mTOR inhibitors and anti-angiogenesis must
be avoided during pregnancy and lactation, and after giving
birth.
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